Neovasc Inc

Neovasc — Non-Deal Roadshow (June 2008)

34 slides from Neovasc's roadshow presentation, June 2008

  1. Slide 1: Neovasc Inc.

    Neovasc Inc. June, 2008 Alexei Marko, CEO Chris Clark, CFO

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements Statements contained herein that are not based on historical or current fact, including without limitation statements containing the words “anticipates,” “believes,” “may,” “continues,” “estimates,” “expects,” and “will” and words of similar import, constitute “forward-loo

  3. Slide 3: Agenda

    Agenda > Neovasc today Product platforms Growth drivers Financial highlights

  4. Slide 4: Neovasc at a Glance

    Neovasc at a Glance • Medical device company focused on solving clinical problems for MDs in the vascular field • Targeting large underserved markets – Peripheral artery disease (PAD) – Refractory angina • Initial products approved in US/EU and generating early sales (~$1.5M in 2007) • Strong pipeli

  5. Slide 5: Mission

    Mission • Neovasc develops vascular devices for use by interventional cardiologists and radiologists, and vascular surgeons. • We focus on devices that solve clinical problems and benefit medical practice by making patient care faster, easier and more effective.

  6. Slide 6: Company Origin

    Company Origin Medical Ventures Corp. (Vancouver, Canada) TSXV: MEV AMEX application • Metricath arterial catheters • PeriPatch surgical tissue Neovasc Medical Ltd. B-Balloon Ltd. (Israel) (Israel) • vascular catheter technologies • vascular catheter technologies July 1, 2008

  7. Slide 7: Target Markets

    Target Markets Disease Market Size Customers Cardiovascular US ~16M people • Cardiovascular surgeons Disease (CVD) US ~1.2M new/yr • Vascular surgeons $156B US overall cost • Interventional cardiologists $18B US devices • Interventional radiologists Peripheral Artery US ~8M people • Vascular surgeon

  8. Slide 8: Clinical Advisors

    Clinical Advisors Our Advisors include leading practitioners and opinion leaders Metricath Ostial Products Reducer Dr. David Allie* Dr. Gary Ansel Dr. Shmuel Banai* Dr. Rajesh Dave* Dr. Arik Finkelstein* Dr. Robert Bonow* Dr. Jorge Saucedo Dr. Michael Jaff Dr. Elazar Edelman* Dr. Robert Tahara* Dr.

  9. Slide 9: Management and Board

    Management and Board Management Board of Directors Alexei Marko - CEO Paul Geyer (Chairman) Chris Clark - CFO Steve Rubin Eyal Sandach – Exec VP Israel Doug Janzen Brian McPherson – VP Operations Boaz Lifschitz Sean Moore – VP Sales Bill O’Neill MD Cynthia Roney – VP Marketing Dr. Jane Hsiao Amir Mi

  10. Slide 10: Agenda

    Agenda Neovasc today > Product platforms Growth drivers Financial highlights

  11. Slide 11: Two Growth Platforms

    Two Growth Platforms Interventional Products Surgical Products Products for use during Products for use during open catheter-based treatment of or minimally invasive surgical vascular disease procedures

  12. Slide 12: Interventional Products

    Interventional Products Metricath® Arterial Measurement System • Precise measurement of arteries and stents for device selection and optimization • Fast and cost effective • FDA cleared and EU approved Ostial Dilatation balloons and stent systems for “ostial” locations Products • Enable precise plac

  13. Slide 13: Metricath

    Metricath • Console and disposable balloon catheters • Precise artery and stent lumen size measurements for: - selecting stent or treatment catheter size - ensuring complete stent expansion • Metricath Libra “measure only” product FDA cleared and CE marked • Metricath Gemini “measure-and-treat” prod

  14. Slide 14: Ostial Products

    Ostial Products Difficult to properly locate a stent or balloon at the origin of an artery where it branches from the aorta (“the ostium”) • Time consuming and frustrating for MD’s • ~200,000 ostial lesions treated annually in US X X • risk of clots • artery still blocked • can’t re-access

  15. Slide 15: Ostial Products

    Ostial Products Dual balloon system guides precise placement of balloon or stent at the ostium • Significantly reduces procedure time and hassle for MD • Reduces potential complications and/or need for multiple treatments • First ostial balloon products into US market in 2009 • First ostial stent sy

  16. Slide 16: Reducer

    Reducer • Treats refractory angina – chronic heart pain from inadequate blood flow - ~2M patients in the US - drugs not providing relief - stents / surgery failed or not an option • Implanted in the coronary sinus to restrict outflow from coronary arteries • Resulting back-pressure improves blood fl

  17. Slide 17: Reducer

    Reducer • Compelling clinical data from first human trial - published in JACC - No device related adverse events or complications - Significant improvement in majority of subjects • Filing for EU approval in 2009 • Initial plan in place for US FDA trial (PMA trial) • Key US trial investigators ident

  18. Slide 18: Surgical Products

    Surgical Products PeriPatch™ Tissue for surgical repair • Used as general patch material • 20+ year implant history • “Remodelable” version in 2009 Vascufix™ Peripheral vascular patch • Used for peripheral repair • 20+ year implant history • Targets carotid EA and related procedures Aegis™ Staple li

  19. Slide 19: PeriPatch

    PeriPatch • Cross-linked bovine and equine pericardial tissue • Treatment process creates implantable, biocompatible collagen tissue that retains physical characteristics of natural tissue • Initially developed for heart valve applications (20+ year implant history) • Adapted for general surgical us

  20. Slide 20: VascuFix

    VascuFix • Implantable tissue patches tailored specifically for peripheral vascular repair procedures • Thin, uniform tissue ideal for precision applications such as artery repair • Same mft. process as PeriPatch • Primary use is for carotid endarterectomies (150k cases/year in US) • FDA cleared

  21. Slide 21: Aegis

    Aegis • Used in minimally invasive thoracic and bariatric surgery (200k/yr bariatric surgeries in US, growing @30%) • Buttress of tissue under staples to minimize leakage of blood/fluid (a major complication in bariatric surgery) • Does not dislodge during manipulation • Fits standard Ethicon & US S

  22. Slide 22: Contract Services

    Contract Services • OEM tissue supply to multiple endovascular valve companies • Contract manufacturing • Product development services Provides near term revenue generation with significant potential for future growth

  23. Slide 23: Sales Channels

    Sales Channels Product Distribution Strategy US • Interventional Direct • Reps located in key markets products • Situated near multiple hospitals • VascuFix • Call on interventionists AND surgeons • Developing early customers and markets for initial products • Expand sales force in 2009 as new produ

  24. Slide 24: Intellectual Property

    Intellectual Property • Strong IP in place or pending to protect catheter products • Combination of trade secrets and patent protection for tissue products • Freedom to practice opinions obtained for Metricath, Ostial and Reducer products

  25. Slide 25: Agenda

    Agenda Neovasc today Product platforms > Growth drivers Financial highlights

  26. Slide 26: Market Drivers

    Market Drivers 1. Aging population and better management of coronary vascular disease results in growing incidence of peripheral artery disease and refractory angina 2. Physicians seeking better clinical tools to ease and speed procedures 3. Trend to “hybrid” MD’s who perform both catheter- based an

  27. Slide 27: Growth Strategy

    Growth Strategy Effectively commercialize a portfolio of vascular products though both internal development and strategic acquisition • Increased bandwidth for research and development through Israeli acquisitions • Suppressed acquisition environment and buyers market for pre- or early-commercial te

  28. Slide 28: Value Building Events

    Value Building Events 2008 2009 2010 2nd half 1st half 2nd half 1st half AMEX Listing X Metricath Gemini FDA approval X Ostial Balloon products approved in EU X Ostial Balloon products approved in US X Ostial Stent products approved in EU X Remodelable tissue approved in US X Reducer CE mark applica

  29. Slide 29: Agenda

    Agenda Neovasc today Product platforms Growth drivers > Financial highlights

  30. Slide 30: Historical Revenues

    Historical Revenues Year over Year Revenue Growth 1600 1400 1200 1000 $000s 800 600 400 200 0 2006 2007 Contract 179 308 Vascular 187 258 Surgical 717 952 Year

  31. Slide 31: Balance Sheet

    Balance Sheet DRAFT BALANCE SHEET* $Ms CURRENT ASSETS • Concurrent financing $8.3m, CASH 8.5 sufficient runway for next ACCOUNTS RECEIVABLE 0.5 financing in the first half of 2009 INVENTORY 0.5 PROPERTY 1.5 • Intangible assets includes INTANGIBLE ASSETS 24.5 acquired technologies, patents 35.5 and r

  32. Slide 32: Capitalization

    Capitalization* Shares outstanding ~ 17.7M ~ 22.9M (fully diluted) July 1 financing terms • Private placement for ~$8.3M at $4.00 per unit • Unit comprises 1 common share with 4 month hold, and 0.62 warrants (18 month, $5.00 exercise price) Estimated market capitalization • $55M (Based on 6 month av

  33. Slide 33: Summary

    Summary Underserved and growing markets Market Focus in vascular medicine Growth in PAD and evolution of Market opportunity vascular practices Develop & acquire suite of Business model products to meet needs of MDs Experienced management, Leadership directors and clinical advisors Strong technology

  34. Slide 34: Slide 34

Neovasc — Non-Deal Roadshow (June 2008) on 6ix